Dr. Hongyun Zhao 赵洪云
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and immunotherapy for lung cancer and nasopharyngeal carcinoma. Conducts clinical trials for new anti-tumor drugs, with a focus on Phase I studies.
Dr. Zhao is Chief Physician and Deputy Director of the Clinical Research Department at Sun Yat-sen University Cancer Center. Dr. Zhao trained at Prince of Wales Hospital (2003) and MD Anderson Cancer Center (2016–2017). Research focuses on new drug development and treating advanced lung and nasopharyngeal cancers. Dr. Zhao has led over 30 Phase I–IV clinical trials, including studies on osimertinib, nivolumab, and toripalimab.
Professional roles
- Vice Chair, Youth Committee of the Clinical Research of Anti-tumor Drugs Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Clinical Research of Anti-tumor Drugs Professional Committee, China Anti-Cancer Association
- Member, Cancer Science Popularization and Prevention Professional Committee, China Anti-Cancer Association
- Designated Chair, Lung Cancer Precision Treatment and Clinical Research Professional Committee, Guangdong Clinical Medical Association
Name order: in Chinese the family name comes first (Zhao Hongyun). Papers usually list the name as Hongyun Zhao or Zhao H.
Selected publications
207 papers on PubMed matched by name and affiliation; 47 as first or senior author since 2016. Most recent first- or senior-author papers:
- BMC Cancer, 2026 (senior author): Correction to: Early change of plasma Epstein-Barr virus DNA load and the viral lytic genome level could positively predict clinical outcome in recurrent or metastatic nasopharyngeal carcinoma receiving anti-programmed cell death 1 monotherapy. PubMed 42587281
- Cancer Cell Int, 2026 (senior author): Correction: Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. PubMed 42304459
- Cancer Cell, 2026 (senior author): JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1(G2032R) resistance mutation in NSCLC: The first-in-human phase 1 trial. PubMed 42030931
- Oncologist, 2026 (senior author): Phase I study of Y101D, a bispecific antibody targeting PD-L1 and TGF-β in patients with advanced solid tumors. PubMed 42104927
- Clin Cancer Res, 2025 (senior author): Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study. PubMed 40260627
- EClinicalMedicine, 2025 (senior author): Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK (+) and ROS1 (+) non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial. PubMed 41146927
- Cell Rep Med, 2025 (senior author): Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study. PubMed 41045933
- BMC Med, 2025 (senior author): Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial. PubMed 40866861
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion